top of page
検索

European Commission approves Amneal's Adcomfo omalizumab biosimilar to Xolair

執筆者の写真: nuaxia
nuaxia
6 時間前
読了時間: 1分

Amneal has received European Commission approval for Adcomfo, an omalizumab biosimilar to Xolair, covering several allergic and inflammatory conditions and expanding competition in the European biologics market.


Amneal announced on 17 November 2026 that the European Commission had approved Adcomfo (omalizumab), a biosimilar to Xolair, for specified indications including severe allergic asthma, chronic spontaneous urticaria and chronic rhinosinusitis with nasal polyps.


The biosimilar was developed by Kashiv BioSciences in collaboration with Alvotech, with European commercialisation rights held by ADVANZ PHARMA; the decision follows UK authorisation in March 2026, while the separate US application remains under FDA review, making this a new European approval rather than a US regulatory milestone.

Field

Content

Company

Amneal

Medicine

Adcomfo (omalizumab)

Reference Medicine

Xolair

Regulatory Authority

European Commission

Approval Date

17 November 2026

Approval Type

EU biosimilar marketing authorisation

Therapeutic Areas

Allergy immunology and respiratory medicine

Indication One

Severe allergic asthma

Indication Two

Chronic spontaneous urticaria

Indication Three

Chronic rhinosinusitis with nasal polyps

Product Classification

Monoclonal antibody biosimilar

Development Company

Kashiv BioSciences

Development Collaboration

Alvotech

European Commercialisation Rights

ADVANZ PHARMA

Earlier UK Approval

March 2026

US Regulatory Status

FDA application under review according to supplied summary

Primary Source

https://investors.amneal.com/news/press-releases/press-release-details/2026/Amneal-Announces-European-Approval-of-Adcomfo-Omalizumab-a-Biosimilar-to-XOLAIR/default.aspx


Discover how nuaxia can support your next medical education initiative:

 
 
 

コメント

5つ星のうち0と評価されています。
まだ評価がありません

評価を追加
bottom of page